CAS 2170729-29-8

AT-007

CAS : 2170729-29-8

AT-007 is an orally active CNS penetrant Aldose Reductase inhibitor for the treatment of Galactosemia (IC50: 100 pM).

Formule : C₁₇H₁₀F₃N₃O₃S₂

Degré de pureté : 99.36%

Couleur et forme : Solid

Masse moléculaire : 425.4

Ref: TM-T10393

2-(4-Oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid

CAS : 2170729-29-8

Formule : C₁₇H₁₀F₃N₃O₃S₂

Degré de pureté : 98%

Masse moléculaire : 425.4048

Ref: IN-DA01V487

2-(4-Oxo-3-((5-(Trifluoromethyl)Benzo[D]Thiazol-2-Yl)Methyl)-3,4-Dihydrothieno[3,4-D]Pyridazin-1-Yl)Acetic Acid

CAS : 2170729-29-8

2-(4-Oxo-3-((5-(Trifluoromethyl)Benzo[D]Thiazol-2-Yl)Methyl)-3,4-Dihydrothieno[3,4-D]Pyridazin-1-Yl)Acetic Acid

Degré de pureté : 98%

Masse moléculaire : 425.4g/mol

Ref: 54-PC108452

AT-007

CAS : 2170729-29-8

AT-007

Degré de pureté : ≥98%

Masse moléculaire : 425.4g/mol

Ref: 54-BUP02404

2-(4-Oxo-3-((5-(trifluoromethyl)benzo[d]thiazol-2-yl)methyl)-3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid

CAS : 2170729-29-8

Formule : C₁₇H₁₀F₃N₃O₃S₂

Degré de pureté : ≥98%

Masse moléculaire : 425.4

Ref: 10-F546907

AT-007

CAS : 2170729-29-8

AT-007 is an investigational pharmaceutical compound, which is a small molecule inhibitor derived from advanced synthetic chemistry processes. It functions through the inhibition of aldose reductase, a key enzyme involved in the polyol pathway. By impeding this enzyme, AT-007 effectively reduces the accumulation of harmful sugar alcohols in cells, which otherwise contribute to cellular damage and the pathophysiology of certain metabolic disorders.

Formule : C₁₇H₁₀F₃N₃O₃S₂

Degré de pureté : Min. 95%

Masse moléculaire : 425.4 g/mol

Ref: 3D-VLD72929